Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Majem, Margarita
Replay, NCT03526887: Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC	Completed	2	73	Europe	Pembrolizumab, KEYTRUDA	Spanish Lung Cancer Group	Lung Cancer	12/22	03/23
2SMALL, NCT04253145 / 2019-001553-12: Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.	Recruiting	1/2	184	Europe	PM 01183, Lurbinectidin, Atezolizumab, Tecentriq	Fundacion Oncosur, Fundación ONCOSUR	Carcinoma, Small Cell Lung	05/25	05/25
NCT02941458: Thoracic Tumours Register	Recruiting	N/A	10000	Europe		Spanish Lung Cancer Group	Thoracic Tumors	12/25	12/30
Paredes, Alfredo
NCT02941458: Thoracic Tumours Register	Recruiting	N/A	10000	Europe		Spanish Lung Cancer Group	Thoracic Tumors	12/25	12/30

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Majem, Margarita
Replay, NCT03526887: Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC	Completed	2	73	Europe	Pembrolizumab, KEYTRUDA	Spanish Lung Cancer Group	Lung Cancer	12/22	03/23
2SMALL, NCT04253145 / 2019-001553-12: Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.	Recruiting	1/2	184	Europe	PM 01183, Lurbinectidin, Atezolizumab, Tecentriq	Fundacion Oncosur, Fundación ONCOSUR	Carcinoma, Small Cell Lung	05/25	05/25
NCT02941458: Thoracic Tumours Register	Recruiting	N/A	10000	Europe		Spanish Lung Cancer Group	Thoracic Tumors	12/25	12/30
Paredes, Alfredo
NCT02941458: Thoracic Tumours Register	Recruiting	N/A	10000	Europe		Spanish Lung Cancer Group	Thoracic Tumors	12/25	12/30